NIH Analyzes “Interactive Treatment” For Relief Of Chronic Pain And Focuses On Re-ducing Opioid Misuse; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Deliver Non-Opioid Relief From Acute And Chronic Pain
In its own publication, NIH Medline Plus Magazine, the National Institutes of Health (NIH) published an analysis of pain management titled, “From Opioids To Mindfulness: A New Approach To Chronic Pain.” The integrative technique is focused on reducing opioid dependence. Results are a 32% reduction in opioid dose, 63% reduction in number of patients who misuse opioids, a 22% decrease in pain-related impairment and a 50% reduction in opioid cravings, the analysis finds.
The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).
NIH Analyzes “Interactive Treatment” For Relief Of Chronic Pain And Focuses On Reducing Opioid Misuse; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Deliver Non-Opioid Relief From Acute And Chronic Pain
The report in NIH’s NIH Medline Plus Magazine finds that the strategy — including lower back pain, arthritis and addiction — calls for a combination of social workers, mindfulness and physicians. The Dr. who discusses this practice has been for the past 15 years as a clinical social worker. NIH Analyzes “Interactive Treatment” For Relief Of Chronic Pain And Focuses On Reducing Opioid Misuse; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Deliver Non-Opioid Relief From Acute And Chronic Pain.
The Electromedical Technologies, Inc.’s (OTCQB: EMED) FDA cleared and non-invasive line of WellnessPro Plus™ products offer pain relief
For 2021, Matthew Wolfson, CEO, anticipates that patients who have experienced chronic pain relief from the bioelectronics and electro-modulation delivered by the Wellness Pro Plus devices warrant the investment in year-end inventory build-up. In anticipation of a rush for the product in early 2021, the company has invested $4.2 Million as it has built and paid for a 1,200+ unit inventory in preparation for attracting hundreds more medical practitioners and distributors in 2021, the Company said.
Electromedical Technologies, Inc. (OTCQB: EMED) focuses on how to relieve chronic and acute pain with non-invasive devices which do not have addictive pain killer drugs, which may have the side effect of addiction to opioids. It saves overworked medical staffs from dealing with more complications from acute pain.
Already, Electromedical Technologies, Inc. (OTCQB: EMED) has built more wellnessPro Plus™ device inventory for an anticipated accelerated demand in 2021 for the product. As an alternative to opioid-addicting pharmaceuticals, the device solves acute and chronic pain for patients. NIH Analyzes “Interactive Treatment” For Relief Of Chronic Pain And Focuses On Reducing Opioid Misuse; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Deliver Non-Opioid Relief From Acute And Chronic Pain.
The WellnessPlus POD Portal For Remote Realtime Monitoring Of Treatment
Electromedical Technologies, Inc. (OTCQB: EMED) offers a non-invasive solution via devices which do not incur more opioid addiction. In the future, the company plans to offer physicians, providers and trained technicians the smaller and feature-intensive WellnessPlus POD.
The POD model offers a special feature: a portal that enables supervising staff the ability to monitor in real time how a patient is receiving pain relief from the device. In a time of home-bound pandemic suffering patients, this is an important new feature. NIH Analyzes “Interactive Treatment” For Relief Of Chronic Pain And Focuses On Reducing Opioid Misuse; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Deliver Non-Opioid Relief From Acute And Chronic Pain.
Goldman Small Cap Research Report Projects EMED Will Reach $17 Million By 2022
Partly as a result of its bullishness on the future growth of the to-be-introduced WellnessPlus POD, the Goldman Small Cap Research report projects EMED conservatively will reach $17 million in volume by 2022, and perhaps as high as $22 million with unit sales of its devices that year reaching 80,000 or 90,000 units. Goldman Small Cap Research projected EMED’s FDA cleared WellnessPro Plus device will exponentially grow in sales.
The analysis is especially bullish about the sales of the to-be-introduced in late 2021 after an anticipated FDA clearance of the WellnessPlus POD, which features a remote monitoring portal. The telemedicine-like remote portal will enable physicians and technicians to monitor in real time a remote view of therapy effectiveness — a trend as medical facilities are stressed due to COVID-19. The FDA has just issued emergency use authorizations for remote devices.
Remote Control Treatment Monitoring Trending In Medical Field
Certain remote or patient-wearing monitoring devices may enable physicians and caretakers to operate a medical device from a non co-located space with the patient. The strain of COVID-19 pandemic patients overwhelming medical facilities requires medical innovation and remote monitoring. Electromedical Technologies, Inc.’s (OTCQB: EMED) WellnessPlus POD with remote monitoring portal could be a key pain-treatment device.
Telemedicine Devices In Demand During Spike In COVID-19 Patients
In medical fields ranging from treatment of health and wellness and mental health, the use of remote monitoring devices enables medical facilities to provide treatments for more patients and offer real time monitoring by medical providers.
Electromedical Technologies, Inc. (OTCQB: EMED) Payment/Subscription Model For Its Devices Is Seen As A Positive, According To Goldman Report
The company has a combination purchase down payment/subscription payment revenue model which provides recurring revenue for sales of its devices. The upbeat forecast by Goldman SmallCap Research is largely based on prior sales of the FDA cleared Wellness Pro Plus. Analyst Rob Goldman wrote that he was especially impressed with its telemedicine-like portal feature that permits physicians or technicians to monitor in real time and from a remote location how the wearable POD therapy is delivering relief from acute and chronic pain.
EMED Offers Devices Which Provide Alternatives To Opioid-Addicting Pain Killer Drugs
Electromedical Technologies, Inc. (OTCQB: EMED has successfully marketed its non-invasive FDA-cleared WellnessPro Plus™ as an alternative treatment to opioid pain killer pharmaceuticals, which can be addictive.
The WellnessPlus Pod Seen Debuting In Late 2021, After Anticipated FDA Clearance
Electromedical Technologies, Inc. (OTCQB: EMED) will debut in late 2021 the WellnessPlus POD, a smaller, professional, less costly device that features a special portal for telemedicine-like real time monitoring by physicians. The WellnessPro POD links doctors/technicians and patients with that feature and is less costly, smaller, portable and offers a remote POD portal. The device also provides a unique financial sales structure for the Company, combining a down payment purchase with a recurring monthly subscription services fee.
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Stock Market Press
110 Wall St.
New York, NY 10005 email@example.com Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press